BMO Capital lowers National Health Investors target to $80
BMO Capital analyst Juan Sanabria maintained an Outperform rating on National Health Investors but lowered the price target to $80 from $90, adjusting the valuation outlook while retaining a positive stance on the stock.
*this image is generated using AI for illustrative purposes only.
BMO Capital analyst Juan Sanabria maintained an Outperform rating for National Health Investors (NYSE: NHI) while lowering the price target to $80 from $90. The adjustment reflects a revised valuation outlook for the healthcare real estate investment trust. The recommendation suggests confidence in the company's fundamental performance despite the reduced target.
Rating and Price Target Details
The firm's decision to keep the Outperform rating indicates a belief that the stock will outperform the market average or its sector peers. However, the price target reduction signals a more conservative view on the near-term upside potential.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $90 |
| New Price Target | $80 |
National Health Investors specializes in financing healthcare real estate. The revised target follows a periodic review of the company's financial position and market conditions.
What specific market conditions or valuation metrics drove the $10 reduction in the price target?
How might rising interest rates impact NHI's cost of capital and future dividend sustainability?
Could this price target adjustment signal a broader trend for healthcare REITs in the current economic climate?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
